Dr. reddy's receives approval to conduct phase 3 clinical trial for sputnik v vaccine in india

Hyderabad, india--(business wire)--dr. reddy's laboratories ltd (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy) announced today that it has received approval from the drugs control general of india (dcgi) to conduct phase 3 clinical trial for the sputnik v vaccine in india. the phase 3 study of sputnik v will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in india. earlier, the data and safety monitoring board (dsmb) revi
RDY Ratings Summary
RDY Quant Ranking